BC Week In Review | Jan 19, 2018
Clinical News

FDA approves Teva's Trisenox for newly diagnosed APL

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA approved Trisenox arsenic trioxide plus tretinoin to treat adults with newly diagnosed low-risk acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Oct 20, 2017
Clinical News

FDA grants Priority Review to Teva's Trisenox sNDA

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA accepted and granted Priority Review to an sNDA for Trisenox arsenic trioxide plus all-trans retinoic acid (ATRA) for induction of remission and consolidation in patients with...
BC Innovations | Jul 10, 2017
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting GLI1 alone or in combination with PI3K could help treat squamous cell carcinoma (SCC) of the lung. In lung tissue samples from patients,...
BC Innovations | May 31, 2017
Distillery Therapeutics

Cancer

INDICATION: Acute promyelocytic leukemia (APL) Patient sample, cell culture and mouse studies suggest inhibiting the TRIB3 - PML interaction could help treat APL. In AML patients, bone marrow levels of TRIB3 were higher in than in...
BC Week In Review | Nov 22, 2016
Clinical News

Trisenox regulatory update

The European Commission approved a label expansion for Trisenox arsenic trioxide from Teva to include treatment of acute promyelocytic leukemia (APL) in combination with retinoic acid. The product is approved in the EU for induction...
BC Week In Review | Oct 24, 2016
Clinical News

Trisenox arsenic trioxide regulatory update

EMA’s CHMP recommended expanding the label of Trisenox arsenic trioxide from Teva to include treatment of newly diagnosed, low to intermediate risk acute promyelocytic leukemia (APL) in combination with retinoic acid. Trisenox is approved in...
BC Innovations | Sep 1, 2016
Translation in Brief

Kite takes CARs off the shelf

As autologous CAR T cell products are making their way through the clinic, several cell therapy companies are working to develop off-the-shelf variants for faster treatment and easier manufacturing. Kite Pharma Inc. (NASDAQ:KITE) is the...
BC Innovations | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors BRAF; smoothened (SMO) Studies in patient samples and cell culture suggest BRAF and SMO inhibitors could be useful for treating ameloblastomas, which are...
BC Week In Review | Dec 9, 2013
Company News

Cell Therapeutics, Teva deal

Cell Therapeutics received a $5 million milestone payment from Teva under a 2005 deal in which Cephalon Inc. acquired Cell Therapeutics' Trisenox arsenic trioxide for acute promyelocytic leukemia . Teva acquired Cephalon in 2011. The payment...
Items per page:
1 - 10 of 140